JP2012507577A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012507577A5 JP2012507577A5 JP2011535207A JP2011535207A JP2012507577A5 JP 2012507577 A5 JP2012507577 A5 JP 2012507577A5 JP 2011535207 A JP2011535207 A JP 2011535207A JP 2011535207 A JP2011535207 A JP 2011535207A JP 2012507577 A5 JP2012507577 A5 JP 2012507577A5
- Authority
- JP
- Japan
- Prior art keywords
- carboxy
- disease
- disorder
- group
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 23
- 239000000203 mixture Substances 0.000 claims 18
- 230000002757 inflammatory effect Effects 0.000 claims 17
- -1 (3-carboxy) propyl Chemical group 0.000 claims 15
- 208000035475 disorder Diseases 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 10
- 238000000034 method Methods 0.000 claims 9
- 230000003287 optical effect Effects 0.000 claims 9
- 102000004127 Cytokines Human genes 0.000 claims 8
- 108090000695 Cytokines Proteins 0.000 claims 8
- 102000013462 Interleukin-12 Human genes 0.000 claims 8
- 108010065805 Interleukin-12 Proteins 0.000 claims 8
- 102000013264 Interleukin-23 Human genes 0.000 claims 8
- 108010065637 Interleukin-23 Proteins 0.000 claims 8
- 229940117681 interleukin-12 Drugs 0.000 claims 8
- 229940124829 interleukin-23 Drugs 0.000 claims 8
- 206010061218 Inflammation Diseases 0.000 claims 7
- 230000004054 inflammatory process Effects 0.000 claims 7
- 239000005022 packaging material Substances 0.000 claims 6
- 150000002632 lipids Chemical class 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 230000009286 beneficial effect Effects 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 claims 3
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 claims 3
- 229950006137 dexfosfoserine Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 2
- 208000023178 Musculoskeletal disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims 2
- 208000037976 chronic inflammation Diseases 0.000 claims 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 2
- 208000018631 connective tissue disease Diseases 0.000 claims 2
- 208000010643 digestive system disease Diseases 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 2
- 210000004907 gland Anatomy 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical group 0.000 claims 2
- 239000007943 implant Substances 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 208000011488 immunodeficiency 19 Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 208000017445 musculoskeletal system disease Diseases 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000017443 reproductive system disease Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19322008P | 2008-11-06 | 2008-11-06 | |
| US61/193,220 | 2008-11-06 | ||
| PCT/IL2009/001049 WO2010052718A1 (en) | 2008-11-06 | 2009-11-05 | Oxidized lipid compounds and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015031816A Division JP2015129157A (ja) | 2008-11-06 | 2015-02-20 | 酸化脂質化合物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012507577A JP2012507577A (ja) | 2012-03-29 |
| JP2012507577A5 true JP2012507577A5 (enExample) | 2012-12-20 |
| JP5752599B2 JP5752599B2 (ja) | 2015-07-22 |
Family
ID=42152558
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011535207A Expired - Fee Related JP5752599B2 (ja) | 2008-11-06 | 2009-11-05 | 酸化脂質化合物およびその使用 |
| JP2015031816A Pending JP2015129157A (ja) | 2008-11-06 | 2015-02-20 | 酸化脂質化合物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015031816A Pending JP2015129157A (ja) | 2008-11-06 | 2015-02-20 | 酸化脂質化合物およびその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9206206B2 (enExample) |
| EP (3) | EP2348866B1 (enExample) |
| JP (2) | JP5752599B2 (enExample) |
| KR (1) | KR20110095288A (enExample) |
| CN (2) | CN104788492A (enExample) |
| AU (1) | AU2009312355C1 (enExample) |
| CA (1) | CA2740726A1 (enExample) |
| ES (1) | ES2534044T3 (enExample) |
| HK (2) | HK1206199A1 (enExample) |
| MX (1) | MX2011004773A (enExample) |
| NZ (1) | NZ592357A (enExample) |
| RU (2) | RU2532546C2 (enExample) |
| WO (1) | WO2010052718A1 (enExample) |
| ZA (1) | ZA201102872B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| US7807847B2 (en) | 2004-07-09 | 2010-10-05 | Vascular Biogenics Ltd. | Process for the preparation of oxidized phospholipids |
| US9006217B2 (en) | 2007-01-09 | 2015-04-14 | Vascular Biogenics Ltd. | High-purity phospholipids |
| US8569529B2 (en) | 2007-01-09 | 2013-10-29 | Vascular Biogenics Ltd. | High-purity phospholipids |
| US8999960B2 (en) | 2008-10-08 | 2015-04-07 | Vascular Biogenics Ltd. | Oxidized thiophospholipid compounds and uses thereof |
| KR20110095288A (ko) * | 2008-11-06 | 2011-08-24 | 바스큘라 바이오제닉스 리미티드 | 산화된 지질 화합물 및 이의 용도 |
| WO2012119781A2 (en) * | 2011-03-10 | 2012-09-13 | University Of Geneva | Novel lipids, phospholipids, phospholipid and lipid compositions and their use |
| SG11201400208PA (en) | 2011-09-01 | 2014-03-28 | Vascular Biogenics Ltd | Formulations and dosage forms of oxidized phospholipids |
| EP2791101B1 (en) * | 2011-12-12 | 2019-09-18 | Vascular Biogenics Ltd. | Treatment of non-alcoholic steatohepatitis |
| CN106999506A (zh) | 2014-11-26 | 2017-08-01 | 脉管生物生长有限公司 | 氧化脂质以及纤维化的治疗或预防 |
| US9771385B2 (en) * | 2014-11-26 | 2017-09-26 | Vascular Biogenics Ltd. | Oxidized lipids |
| EP3735977A1 (en) * | 2015-07-31 | 2020-11-11 | Vascular Biogenics Ltd. | Motile sperm domain containing protein 2 and cancer |
| ES2963268T3 (es) * | 2015-07-31 | 2024-03-26 | Immunewalk Therapeutics Inc | Proteína 2 que contiene el dominio de esperma móvil e inflamación |
| JP6755530B2 (ja) * | 2016-09-02 | 2020-09-16 | 国立大学法人岩手大学 | 皮膚炎の予防又は治療用医薬組成物 |
| WO2021199003A1 (en) * | 2020-04-02 | 2021-10-07 | Vascular Biogenics Ltd. | Oxidized lipids and treatment or prevention of inflammation or infectious disease caused by coronavirus infection |
| JP7559223B2 (ja) | 2020-08-24 | 2024-10-01 | ギリアード サイエンシーズ， インコーポレイテッド | リン脂質化合物及びその使用 |
| IL301202A (en) | 2020-09-10 | 2023-05-01 | Vascular Biogenics Ltd | Antibodies against MOTILE SPERM DOMAIN CONTAINING PROTEIN 2 and methods of using them |
| TWI925033B (zh) | 2020-10-16 | 2026-05-11 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| AU2023242443A1 (en) * | 2022-03-28 | 2024-08-29 | F. Hoffmann-La Roche Ag | Synthesis of isomerically pure polyol-based phosphoramidites |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5638578B2 (enExample) | 1973-05-18 | 1981-09-08 | ||
| US4166132A (en) | 1977-08-18 | 1979-08-28 | Pfizer Inc. | Antiviral amine derivatives of glycerol and propanediols |
| GB1572226A (en) * | 1977-11-03 | 1980-07-30 | Hoechst Uk Ltd | Pharmaceutical preparations in solid unit dosage form |
| CH642665A5 (en) | 1979-02-08 | 1984-04-30 | Rudolf Berchtold | Process for the preparation of 1-(omega-carboxyalkyl)-2-alkyl- glycero-3-phosphatides |
| US4329302A (en) * | 1980-06-27 | 1982-05-11 | Board Of Regents, The University Of Texas System | Synthetic phosphoglycerides possessing platelet activating properties |
| JPS5993022A (ja) * | 1982-11-16 | 1984-05-29 | Kao Corp | ポリオ−ルエ−テル化合物およびその製造法ならびにこれを含有する化粧料 |
| DE3307925A1 (de) | 1983-03-05 | 1984-09-06 | A. Nattermann & Cie GmbH, 5000 Köln | Neue 0-acyl-alkandiol-phospholipide, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
| US4614796A (en) * | 1983-03-25 | 1986-09-30 | Nippon Shinyaku Co., Ltd. | Liposome and method of manufacture therefor |
| JPS60100544A (ja) | 1983-11-08 | 1985-06-04 | Ono Pharmaceut Co Ltd | 新規なグリセリン誘導体，その製造方法及びその誘導体を含有する薬剤 |
| JPS60104066A (ja) | 1983-11-10 | 1985-06-08 | Ono Pharmaceut Co Ltd | グリセリン誘導体 |
| AT383130B (de) | 1984-05-15 | 1987-05-25 | Chemie Linz Ag | Verfahren zur herstellung von an c1 und c2 verschieden substituierten phosphatidylcholinen und phosphatidylethanolaminen ueber die neuen verbindungen 1-0-tritylglycerophosphocholin beziehungsweise (1-0,n-ditrityl)-glycerophosphoethanolamin |
| US4710579A (en) | 1984-11-09 | 1987-12-01 | Takeda Chemical Industries, Ltd. | 2-(acetoacetyloxy)-3-(octadecyloxy)propyl-3-trimethylammoniopropyl phosphate or a pharmaceutically acceptable salt thereof |
| JPH0617307B2 (ja) | 1984-11-09 | 1994-03-09 | 武田薬品工業株式会社 | 抗腫瘍剤 |
| US4827011A (en) * | 1984-12-10 | 1989-05-02 | American Cyanamid Company | Antihypertensive phosphate derivatives |
| EP0225129B1 (en) | 1985-11-29 | 1989-05-24 | Takeda Chemical Industries, Ltd. | Phospholipid derivatives, their production and use |
| US5061626A (en) * | 1986-03-24 | 1991-10-29 | University Of Sydney | Antigenic anarogues of platelet activating factor |
| EP0299972B1 (en) * | 1986-04-07 | 1992-03-04 | The Upjohn Company | Anthelmintic quaternaryalkyl acylhydrazones, method of use and compositions |
| JPS6294A (ja) | 1986-05-09 | 1987-01-06 | Toyama Chem Co Ltd | 新規なグリセロリン酸誘導体およびその塩並びにそれらの製造法 |
| JPS6354386A (ja) | 1986-08-26 | 1988-03-08 | Takeda Chem Ind Ltd | リン脂質およびその用途 |
| JPS63135395A (ja) | 1986-11-28 | 1988-06-07 | Nippon Oil & Fats Co Ltd | リン脂質誘導体及びその製造方法 |
| US4970233A (en) * | 1987-08-04 | 1990-11-13 | Mchugh John E | Treatment of Acquired Immunodeficiency Syndrome (AIDS) HTLV-111/LAV infections and Acquired Immunodeficiency Syndroms (AIDS) Related Complex (ARC) |
| DE3807123A1 (de) | 1988-03-04 | 1989-09-14 | Boehringer Mannheim Gmbh | Substrate fuer phospholipasen |
| JPH01258691A (ja) | 1988-04-06 | 1989-10-16 | Nippon Oil & Fats Co Ltd | リン脂質誘導体及びその製造方法 |
| JP2534894B2 (ja) | 1988-06-24 | 1996-09-18 | 日本ケミファ株式会社 | 新規なグリセリン誘導体およびその誘導体を含有する血圧降下剤 |
| AU614636B2 (en) * | 1988-07-21 | 1991-09-05 | Ciba Specialty Chemicals Holding Inc. | Corrosion inhibition |
| JPH0248585A (ja) | 1988-08-10 | 1990-02-19 | Nippon Oil & Fats Co Ltd | リン脂質誘導体及びその製造方法 |
| JPH03258740A (ja) | 1990-03-06 | 1991-11-19 | Kao Corp | 液体油、その製造法及びこれを含有する化粧料 |
| ES2019552A6 (es) | 1990-04-11 | 1991-06-16 | Menarini Lab | Procedimiento para la preparacion de glicerofosfolipidos. |
| JP2869572B2 (ja) | 1990-05-14 | 1999-03-10 | 和光純薬工業株式会社 | ホスファチジルコリン誘導体の製造方法 |
| JP3128782B2 (ja) * | 1992-06-12 | 2001-01-29 | 科学技術振興事業団 | 架橋高分子薄膜の製造方法 |
| US5561052A (en) * | 1992-06-18 | 1996-10-01 | Koike; Katsumasa | Process for detecting oxidized lipids and process for forming oxidized lipids |
| FR2714382B1 (fr) * | 1993-12-27 | 1996-02-02 | Roussel Uclaf | Phospholipides vecteur de molécule active, leur préparation et leur utilisation dans des compositions cosmétiques ou dermatologiques. |
| AU1751795A (en) | 1994-03-04 | 1995-09-18 | University Of British Columbia, The | Liposome compositions and methods for the treatment of atherosclerosis |
| JP3364313B2 (ja) * | 1994-03-22 | 2003-01-08 | 株式会社トクヤマ | ポルフィリン／インジウム錯体及び陰イオン感応膜 |
| JPH0859545A (ja) * | 1994-08-24 | 1996-03-05 | Kao Corp | カルボキシエチルエーテル誘導体及びこれを含有する洗浄剤組成物 |
| AU3216695A (en) * | 1994-08-29 | 1996-03-22 | University Of North Carolina At Chapel Hill, The | Lipid analogs for treating viral infections |
| JPH08208548A (ja) | 1995-02-01 | 1996-08-13 | Kao Corp | グリセリン誘導体の製造法 |
| US5660855A (en) * | 1995-02-10 | 1997-08-26 | California Institute Of Technology | Lipid constructs for targeting to vascular smooth muscle tissue |
| US6261597B1 (en) * | 1995-08-31 | 2001-07-17 | Seymour J. Kurtz | Method for treating periodontal disease |
| DE19547022A1 (de) * | 1995-12-15 | 1997-06-19 | Boehringer Mannheim Gmbh | Kovalente Lipid-Phosphonocarbonsäure-Konjugate, deren Herstellung sowie deren Verwendung als antivirale Arzneimittel |
| TW343975B (en) * | 1995-12-15 | 1998-11-01 | Boehringer Mannheim Gmbh | New phospholipid derivatives of phosphonocarboxylic acids, the production thereof as well as their use as antiviral pharmaceutical agents |
| US6096291A (en) * | 1996-12-27 | 2000-08-01 | Biovector Therapeutics, S.A. | Mucosal administration of substances to mammals |
| JP3781877B2 (ja) | 1997-10-03 | 2006-05-31 | 株式会社ムック | アスコルビン酸誘導体またはその塩、および医薬 |
| WO2002053092A2 (en) | 2001-01-04 | 2002-07-11 | Vascular Biogenics Ltd. | Methods employing and compositions containing plaque associated molecules for prevention and treatment of atherosclerosis |
| US6414168B1 (en) * | 1998-12-28 | 2002-07-02 | Caschem, Inc. | Epoxidation of ricinic compounds using a phase-transfer catalyst |
| US6348583B1 (en) * | 1999-08-30 | 2002-02-19 | Bio-Rad Laboratories, Inc. | Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids |
| US7026469B2 (en) * | 2000-10-19 | 2006-04-11 | Wake Forest University School Of Medicine | Compositions and methods of double-targeting virus infections and cancer cells |
| US6670341B1 (en) * | 1999-10-28 | 2003-12-30 | Wake Forest University Health Sciences | Compositions and methods for double-targeting virus infections and targeting cancer cells |
| JP4829454B2 (ja) | 1999-11-30 | 2011-12-07 | ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティ・オブ・アリゾナ | 放射線感受性リポソーム |
| WO2001075168A1 (en) | 2000-03-31 | 2001-10-11 | The Regents Of The University Of California | Control of a gene induced by oxidized lipids in human artery wall cells |
| IL156015A0 (en) | 2000-11-24 | 2003-12-23 | Vascular Biogenics Ltd | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| US6838452B2 (en) * | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| US7132559B2 (en) * | 2001-02-27 | 2006-11-07 | Trustees Of Tufts College | Non-racemic hexafluoroleucine, and methods of making and using it |
| DE10155095A1 (de) | 2001-11-09 | 2003-05-22 | Cognis Deutschland Gmbh | Alkyl(en)ylglycerinethercarbonsäuren |
| CN1526605A (zh) * | 2003-09-23 | 2004-09-08 | 陈东明 | 一种水上游泳池 |
| US7807847B2 (en) * | 2004-07-09 | 2010-10-05 | Vascular Biogenics Ltd. | Process for the preparation of oxidized phospholipids |
| NZ553147A (en) * | 2004-07-09 | 2010-07-30 | Vascular Biogenics Ltd | Improved process for the preparation of oxidized phospholipids |
| US20060194765A1 (en) * | 2004-11-16 | 2006-08-31 | Garcia Joe G N | Methods and compositions using oxidized phospholipids |
| WO2007014001A2 (en) * | 2005-07-21 | 2007-02-01 | The Board Of Trustees Of The Leland Stanford Junior University | Multiplex determination of lipid specific binding moieties |
| US20090074720A1 (en) * | 2005-10-28 | 2009-03-19 | Sabbadini Roger A | Methods for decreasing immune response and treating immune conditions |
| US8137977B2 (en) * | 2006-04-24 | 2012-03-20 | Children's Hospital & Research Center At Oakland | Lipidomic approaches to determining drug response phenotypes in cardiovascular disease |
| US8703179B2 (en) * | 2006-05-11 | 2014-04-22 | Kimberly-Clark Worldwide, Inc. | Mucosal formulation |
| JP2008037763A (ja) * | 2006-08-01 | 2008-02-21 | Adeka Corp | 抗菌剤及び抗菌剤組成物 |
| US9006217B2 (en) * | 2007-01-09 | 2015-04-14 | Vascular Biogenics Ltd. | High-purity phospholipids |
| US8569529B2 (en) * | 2007-01-09 | 2013-10-29 | Vascular Biogenics Ltd. | High-purity phospholipids |
| WO2009070298A1 (en) * | 2007-11-28 | 2009-06-04 | Teva Pharmaceutical Industries, Ltd. | Method of delaying the onset of clinically definite multiple sclerosis |
| US8999960B2 (en) * | 2008-10-08 | 2015-04-07 | Vascular Biogenics Ltd. | Oxidized thiophospholipid compounds and uses thereof |
| KR20110095288A (ko) * | 2008-11-06 | 2011-08-24 | 바스큘라 바이오제닉스 리미티드 | 산화된 지질 화합물 및 이의 용도 |
| MX338931B (es) | 2010-01-05 | 2016-05-06 | Vascular Biogenics Ltd | Composiciones y metodo para tratar gliobastoma (gbm). |
| JP2013516455A (ja) * | 2010-01-05 | 2013-05-13 | バスキュラー バイオジェニックス リミテッド | Ｖｂ−２０１を用いた治療 |
| SG11201400208PA (en) | 2011-09-01 | 2014-03-28 | Vascular Biogenics Ltd | Formulations and dosage forms of oxidized phospholipids |
-
2009
- 2009-11-05 KR KR1020117012700A patent/KR20110095288A/ko not_active Ceased
- 2009-11-05 RU RU2011122729/04A patent/RU2532546C2/ru not_active IP Right Cessation
- 2009-11-05 EP EP09824498.1A patent/EP2348866B1/en not_active Not-in-force
- 2009-11-05 JP JP2011535207A patent/JP5752599B2/ja not_active Expired - Fee Related
- 2009-11-05 CA CA2740726A patent/CA2740726A1/en not_active Abandoned
- 2009-11-05 ES ES09824498.1T patent/ES2534044T3/es active Active
- 2009-11-05 US US13/127,717 patent/US9206206B2/en not_active Expired - Fee Related
- 2009-11-05 EP EP14188359.5A patent/EP2826369A3/en not_active Withdrawn
- 2009-11-05 CN CN201510099273.0A patent/CN104788492A/zh active Pending
- 2009-11-05 EP EP14188368.6A patent/EP2826370A3/en not_active Withdrawn
- 2009-11-05 AU AU2009312355A patent/AU2009312355C1/en not_active Ceased
- 2009-11-05 NZ NZ592357A patent/NZ592357A/xx not_active IP Right Cessation
- 2009-11-05 MX MX2011004773A patent/MX2011004773A/es active IP Right Grant
- 2009-11-05 WO PCT/IL2009/001049 patent/WO2010052718A1/en not_active Ceased
- 2009-11-05 CN CN200980153378.2A patent/CN102271517B/zh not_active Expired - Fee Related
-
2011
- 2011-04-18 ZA ZA2011/02872A patent/ZA201102872B/en unknown
-
2013
- 2013-03-14 US US13/828,883 patent/US20130203707A1/en not_active Abandoned
-
2014
- 2014-09-04 RU RU2014136085A patent/RU2014136085A/ru not_active Application Discontinuation
-
2015
- 2015-02-20 JP JP2015031816A patent/JP2015129157A/ja active Pending
- 2015-07-16 HK HK15106799.3A patent/HK1206199A1/en unknown
- 2015-07-16 HK HK15106798.4A patent/HK1206198A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014136085A (ru) | Окисленные соединения липидов и их применение | |
| JP2010532768A5 (enExample) | ||
| JP2022512482A5 (enExample) | ||
| JP2012097105A5 (enExample) | ||
| JP2008543854A5 (enExample) | ||
| JP2018534286A5 (enExample) | ||
| JP2022520061A5 (enExample) | ||
| JP2015508103A5 (enExample) | ||
| JP2019507781A5 (enExample) | ||
| JP2019537570A5 (enExample) | ||
| JP2017514838A5 (enExample) | ||
| JP2013545730A5 (enExample) | ||
| JP2011509309A5 (enExample) | ||
| DE15177166T1 (de) | S1p-rezeptormodulatoren für die behandlung von multipler sklerose | |
| JP2017141277A5 (enExample) | ||
| JP2018517686A5 (enExample) | ||
| JP2011530545A5 (enExample) | ||
| JP2012508734A5 (enExample) | ||
| JP2009539828A5 (enExample) | ||
| JP2005539045A5 (enExample) | ||
| JP2009536221A5 (enExample) | ||
| JP2016537432A5 (enExample) | ||
| JP2020505354A5 (enExample) | ||
| JP2012532883A5 (enExample) | ||
| JP2016522254A5 (enExample) |